文献速递心境障碍会诊联络精神医学

抗抑郁药在躯体疾病共病抑郁障碍患者中的疗效与耐受性:网络荟萃分析

Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis.
PubMed 文献 · Br J Psychiatry · 2025-01-01

该系统综述与网络荟萃分析纳入115项随机对照试验,评估抗抑郁药在抑郁共病躯体疾病患者中的疗效与耐受性。丙咪嗪、去甲替林、阿米替林、地昔帕明、舍曲林、帕罗西汀、西酞普兰、氟西汀、艾司西酞普兰、米安色林、米氮平和阿戈美拉汀较安慰剂更有效,标准化均数差从-1.01(丙咪嗪)到-0.34(艾司西酞普兰)。舍曲林、丙咪嗪和去甲替林耐受性低于安慰剂,相对风险从1.47(舍曲林)到3.41(去甲替林)。作者认为选择性5-羟色胺再摄取抑制剂(SSRIs)具有最佳获益-风险特征,适合作为一线治疗,而三环类药物高效但耐受性低于SSRIs和安慰剂。

要点

  • 舍曲林和帕罗西汀对最多ICD-11疾病亚组有效(7个亚组中4个)。
  • 舍曲林、丙咪嗪和去甲替林耐受性低于安慰剂,相对风险1.47至3.41。
  • 大多数比较的疗效与耐受性证据确定性为低或极低。

核心结论

  • 抗抑郁药对抑郁共病躯体疾病患者有效,但耐受性是值得关注的问题。
  • 作者认为SSRIs具有最佳获益-风险特征,适合作为一线治疗,三环类药物高效但耐受性低于SSRIs和安慰剂。

研究设计与样本

  • 系统综述与随机对照试验的网络荟萃分析,共纳入115项RCT,其中104项贡献疗效数据(7714名参与者),82项贡献耐受性数据(6083名参与者)。
  • 平均年龄55.7岁,51.9%的参与者为女性,神经系统和心血管循环系统疾病占比最高(分别为26.1%和18.3%的RCT)。
  • 偏倚采用Cochrane Risk-of-Bias 2工具评估,证据确定性采用Confidence in Network Meta-Analysis方法评估,研究方案已预先注册(https://osf.io/9cjhe/)。

主要发现

  • 以下抗抑郁药较安慰剂更有效:丙咪嗪、去甲替林、阿米替林、地昔帕明、舍曲林、帕罗西汀、西酞普兰、氟西汀、艾司西酞普兰、米安色林、米氮平和阿戈美拉汀,标准化均数差从-1.01(丙咪嗪)到-0.34(艾司西酞普兰)。
  • 舍曲林和帕罗西汀对最多ICD-11疾病亚组有效(7个亚组中4个)。
  • 耐受性方面,舍曲林、丙咪嗪和去甲替林耐受性低于安慰剂,相对风险从1.47(舍曲林)到3.41(去甲替林)。
  • 大多数比较的疗效与耐受性证据确定性为低或极低。

临床怎么用

  • 作者认为SSRIs具有最佳获益-风险特征,适合作为一线治疗。
  • 作者认为三环类药物高效但耐受性低于SSRIs和安慰剂。

局限性

  • 大多数比较的疗效与耐受性证据确定性为低或极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antidepressants are effective for depression, but most evidence excludes individuals with comorbid physical conditions. AIMS: To assess antidepressants' efficacy and tolerability in individuals with depression and comorbid physical conditions. METHODS: Systematic review and network meta-analysis of randomised controlled trials (RCTs). Co-primary outcomes were efficacy on depressive symptoms and tolerability (participants dropping out because of adverse events). Bias was assessed with the Cochrane Risk-of-Bias 2 tool and certainty of estimates with the Confidence in Network Meta-Analysis approach. A study protocol was registered in advance (https://osf.io/9cjhe/). RESULTS: Of the 115 included RCTs, 104 contributed to efficacy (7714 participants) and 82 to tolerability (6083 participants). The mean age was 55.7 years and 51.9% of participants were female. Neurological and cardiocirculatory conditions were the most represented (26.1% and 18.3% of RCTs, respectively). The following antidepressants were more effective than placebo: imipramine, nortriptyline, amitriptyline, desipramine, sertraline, paroxetine, citalopram, fluoxetine, escitalopram, mianserin, mirtazapine and agomelatine, with standardised mean differences ranging from -1.01 (imipramine) to -0.34 (escitalopram). Sertraline and paroxetine were effective for the largest number of ICD-11 disease subgroups (four out of seven). In terms of tolerability, sertraline, imipramine and nortriptyline were less tolerated than placebo, with relative risks ranging from 1.47 (sertraline) to 3.41 (nortriptyline). For both outcomes, certainty of evidence was 'low' or 'very low' for most comparisons. CONCLUSION: Antidepressants are effective in individuals with comorbid physical conditions, although tolerability is a relevant concern. Selective serotonin reuptake inhibitors (SSRIs) have the best benefit-risk profile, making them suitable as first-line treatments, while tricyclics are highly effective but less tolerated than SSRIs and placebo.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. De Luca B, Canozzi A, Mosconi C, et al. Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis. Br J Psychiatry. 2025. PMID: 40183137. doi:10.1192/bjp.2025.18

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。